Description

How It Works (What Makes It Interesting)

Studies suggest PNC-27 induces selective cancer cell death through several interconnected mechanisms:

• Membrane HDM-2 targeting – Binds specifically to HDM-2 protein that cancer cells (but not normal cells) express on their plasma membranes, creating the foundation for selective cytotoxicity
• Transmembrane pore formation – Forms ring-shaped pore structures in cancer cell membranes upon HDM-2 binding, causing rapid membranolysis and cell contents extrusion
• Necrotic cell death pathway – Induces necrosis rather than apoptosis, bypassing resistance mechanisms that cancer cells often develop against apoptosis-inducing agents
• Mitochondrial disruption – Penetrates cancer cells and disrupts mitochondrial membranes, creating a dual-targeting effect on both plasma and organelle membranes
• p53-independent action – Functions effectively in cancer cells with deleted, mutated, or overexpressed p53, expanding research applications beyond p53-functional cancers

Common Research Applications

Pancreatic Cancer Models: MIA-PaCa-2 cell lines, TUC-3 metastatic pancreatic cancer, k-ras-transformed pancreatic cancer, pancreatic adenocarcinoma xenografts

Breast Cancer Research: MCF-7 cells, MDA-MB-468 (mutant p53), MDA-MB-157 (p53-null), triple-negative breast cancer models, metastatic breast cancer lines

Hematological Malignancies: Acute myeloid leukemia (U937, OCI-AML3, HL60), chronic myeloid leukemia (K562), acute promyelocytic leukemia, stem-cell lineage leukemia models

Melanoma Studies: A-2058 melanoma cell lines, metastatic melanoma models, drug-resistant melanoma research

Gynecological Cancer Models: Ovarian cancer, endometrial cancer, epithelial ovarian carcinoma, cervical carcinoma research

Other Solid Tumor Research: Lung carcinoma, colon adenocarcinoma, osteosarcoma, p53-deficient cancer models, chemotherapy-resistant cancer line.